KLK3 and Familial prostate cancer: The NICE guideline CG175 [25] has been updated and is due for publication in April 2019 [https://www.nice.org.uk/guidance/indevelopment/gid-ng10057]; it recommends pre-biopsy mpMRI, putting mpMRI as the primary method to investigate those with suspected prostate cancer based on PSA and/or DRE findings.